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Clinical Situation 
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A ischemic stroke (IS) is caused by the transient or permanent disruption 
of the Cerebral Blood Flow (CBF) to a single or several brain areas, during 
≥24h, due to the blockade of a vessel.  
 
The importance of stroke relies on its high impact worldwide since it has 
been estimated that around 11,569,538 of IS events took place worldwide 
during 2010, resulting in the loss of 39,389,408 Disability-Adjusted Life 
Years (DALYs)1. (Figures 1 & 2) 
The Stroke Code (Código Ictus) has been created in 
order to coordinate the journey of the patient to and 
within the hospital section known as Stroke Unit 
(Unidad de Ictus). 
 
The objective is to uncover the main cause of IS 
taking ≤60min, thus provide a suitable acute 
treatment. 
Information addapted from:  
• Guía para el diagnostic y tratamiento del ictus from the 
Sociedad Española de Neurologia (SEN. 2006) used in the 
Spanish hospitals and its review published on 2011 (published 
online on 2014) 
• Guidelines for the Early Management of Patients with Acute 
Ischemic Stroke from the American Heart Association/American 
Stroke Association (AHA/ASA) used by the American doctors. 
(2013) 
Initial emergency evaluation:  
• Analysis of a stroke ranting scales e.g. NIHSS 
• Blood Glucose measurement 
• Baseline electrocardiogram 
• Haematological study 
• Chest radiography (only in Spain) 
• Non-Contrast CT scan evaluation (≤45min) 
Two approaches proposed by SEN:  
1- Measures intended to improve or re-establish the Cerebral Blood Flow (CBF)  
2. Cerebral protection and reparation by 
neuroprotective agents 
First  Steps:  
Weaknesses:  
• It is a highly time-dependent treatment: 
• Only displays effect on 50% of patients, with a rapid action in 21% of the cases2 
• Exhibits a later arterial re-occlusion in, at least, 1/3 of patients 
• 50% of non-responder patients might suffer side-effects of the administration.  
Retrievers 
Coil Retriever 
Merci 1
st approved by FDA (2004) 
Catch 
Symptomatic 
haemorrhage 
Stent 
Retriever 
Solitaire FR 
Approved by FDA (2012) 
Most popular one 
(Figure 3) 
Trevo Vessel perforation 
Revive Haemorrhage 
Aspiration Devises 
Penumbra Still under trial 
Quickcat Not enough data 
PRONTO Not enough data 
NEXT STEP: Intra-arterial (IA) administration of rt-PA using 
Mechanical Thromberectomy devices.  
Benefits:  
 
• Reduction of the systemic con-
centration of the compound 
• Direct infusion into the thrombus 
Risks:  
 
• The technique: catheter manipulation 
• Delayed administration (additional ima-
ging techniques) 
Inhibition of the ISCHEMIC CASCADE (Figure 5) by 
blocking biochemical mediators of the ischemia-reperfusion 
alteration of the “penumbra area” which leads towards 
cellular death.  
Conclusions:  
• The pharmacological approach of IS has reached a point where rt-PA, cannot be object of further improvement.  
 
• The future of this treatment is the combination of rt-PA with either, other compounds or mechanical devices. 
 
• Mechanical thromberectomy is already included hospitalization and treatment protocols, displaying great results. 
 
• Neuroprotective therapies, e.g. Uric Acid, are still under trial but showing promising outcome. 
TREATMENT OF CHOICE:  
Intravenous Recombinant Tissue Plasminogen (IV rtPA) 
FDA approval 1996 
Dose: 9mg/kg with a maximum dose of 90mg 
Viability assessed by CT scan evaluation 
Triggers the fibrinolysis of the thrombus.  
However, no other treatments have shown a higher 
potency or effectiveness than rt-PA. 
1st Phase  
(2012) 
SWIFT 
TREVO-2 
Newer devices 
(Solitaire TR and Trevo) 
were better than Merci.  
2nd Phase  
(2013) 
IMS-III 
SYNTHESIS 
MR RESCUE 
IV rt-PA was still better 
than IA + Mechanical 
thromberectomy 
Imaging-based patient 
selection might improve 
the outcome.  
3rd Phase 
(2014-2015) 
MR CLEAN 
EXTEND-IA 
ESAPE 
SWIFT PRIME 
REVASCAT 
THRACE 
THERAPY 
Endovascular 
approach results in a 
better outcome than 
IV rt-PA 
Trials:  
Results:  
Restorative therapies:  
Enhancement of growth factors (e.g. GAP-43, MARCKS, CAP23, and BDNF). 
Blockade of negative factors (e.g. Nogo-A, chondroitin sulphate, and ephrin A5).  
 
In order to generate new neurons (lateral ventricle and dentate gyrus) which would 
migrate to the ischemic area.7 
 
Antidepressants have shown a positive indirect effect e.g. Fluoxetine (Prozac) at the 
FLAME study. 
Prevention of Haemorrhagic 
Transformation (HT) 
This spectrum of hemorrhages within the area 
the area of the stroke might be produced by the 
reperfusion process performed by rt-PA . 
Approach: NEUROPROTECTIVE AGENTS10 
• Inhibitors of  MMP-2 and MMP-9: these 
matrix metallopeptidases are up-regulated.  
 
• Deferoxamine (DFX):  promising chelating 
agent produced by S. pilosus.  
 
• Estrogen: reduces brain swelling and edema.  
 
• Cilostazol (Pletal):  quinolone-derivate with 
protective effect over endothelium.  
 
• Glybyride (Glibenclamide): DMII medication 
which inhibits sulfonylurea receptors e.g. 
SUR1 which is up-rergulated after ischemia.  
Upregulation of Fibrinogenolysis 
Plasminogen  Plasmin 
Degradation 
of the 
Thrombus 
Reperfussion 
Rt-PA 
Fibrinogenolysis (Figure 6) can increase its catalytic efficiency with the activation of 
the AnnexinA2-plasminogen-tPA complex. Administration of recombinant A2  allows 
to lower the rt-PA dose, preventinig HT.8  
Reperfusion Complication: 
Oxidative Stress 
Early reperfusion can also result in a 
noxious increment of the oxidative stress. 
Uric acid (UA), an endogenous antioxidant, 
in combination with rt-PA attenuates 
middle cerebral artery (MCA) hypertrophy 
in rat models.4  
URICO-ICTUS trial5 tested the combination 
therapy in 500 patients suffering from AIS 
within 10 Spanish Stroke Centres finding 
no significative improvement (P = 0.09).  
1. Pre-treatment hyperglycaemia 
2. Early vessel recanalization (in moderate 
strokes)  
3. Women 
As a result of this positive outcome, a 
new trial is being planned: UPRIGHT6. 
References: 
Objectives 
•To show the current state of the ischemic stroke 
pharmacological treatment combining the Spanish and 
the USA’s guidelines.  
 
•To highlight the importance of the combination of rt-PA 
with mechanical devices.  
 
•To approach the new studies which are being carried 
out just now in research laboratories.  
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Enhancement of the endogenous brain repair system 
 
Rehabilitation 
 
Delivery of 
trophic factors  
(e.g. EPO, GCSF, 
IGF-1, bFGF) 
Drugs with 
trophic effects 
(citicoline, 
cerbrolysin) 
Stem cells 
(neuronal or 
mesenchimal) 
Table 1: The mechanical Thromberectomy devices2 
Rapid Flow Restoration 
  
Administration of rt-PA 
  
Clot Retrieval 
  
Imaging-based Patient Selection 
Characterizing the Ischemic Penumbra 
(Figure 7), the region where the 
reperfusion efforts focus, with new 
penumbral imaging devices.9 
 
Positively tested in three trials: 
DEFUSE, EPITHET and DEFUSE-2.  
 
DEFUSE-3 is being conducted at the 
moment by Stanford University (USA). 
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Figure 5. Events leading from ischemia to  brain cells death. 
Figure 3. Performance of Solitaire FR Revascularization Device3 
Figure 4. Clinical  testing  on 
mechanical thromberectomy 
Research: New Approaches 
Figure 7. The three Ischemic Areas  
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Figure 6. Fibrinogenolysis and the action of rt-PA 
